39 completed, 4 unknown, 4 withdrawn, 2 terminated. 49 Phase 1, 27 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 49 | Completed 39, Unknown 4, Withdrawn 4, Terminated 2 |
| Phase 2 | 27 | Completed 21, Unknown 3, Withdrawn 2, Terminated 1 |
Follow lucentis: new trials by email Literature Review of lucentis trials Research Report on lucentis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating of the Safety, Pharmacokinetics and Pharmacodynamics of QL1205 and Lucentis® in Patients With Wet AMD lucentis, QL1205 - Wet Age-related Macular Degeneration | Phase 1 | Completed | Qilu Pharmaceutical Co., Ltd. | 48 | 2017-12-20 | 2019-04-11 |
| The Effect of Intravitreal Ranibizumab on Visual Acuity and Hard Exudate Resolution in the Treatment of Diabetic Macular Edema With Center Involved Edema and Lipid Exudates ranibizumab 0.3mg - Diabetic Macular Edema, Hard Lipid Exudates | Phase 1 / Phase 2 | Completed | South Coast Retina Center; Carson, McBeath, Boswell, Inc. | 25 | 2015-08-01 | 2021-07-08 |
| Study of DS-7080a for the Treatment of Macular Degeneration DS-7080a, Ranibizumab - Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema | Phase 1 | Completed | Daiichi Sankyo | 56 | 2015-07-01 | 2018-05-09 |
| Prophylactic Ranibizumab for Exudative Age-Related Macular Degeneration Ranibizumab 0.5mg - Age-related Macular Degeneration | Phase 1 / Phase 2 | Completed | Leonard Feiner, MD, PhD | 4 | 2015-05-01 | 2018-08-28 |
| Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone Acetonide Ranibizumab,, Triamcinolone acetonide - CYSTOID MACULAR EDEMA | Phase 1 | Completed | Soll Eye | 4 | 2014-11-01 | 2018-09-11 |
| Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration Ranibizumab 0.5mg - Age-related Macular Degeneration | Phase 1 / Phase 2 | Completed | Southern California Desert Retina Consultants, MC | 108 | 2014-09-17 | 2022-08-25 |
| Safety and Efficacy of Ranibizumab for Diabetic Macular Edema Ranibizumab - Diabetic Macular Edema | Phase 1 / Phase 2 | Completed | Justis Ehlers | 27 | 2014-06-24 | 2020-11-03 |
| Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD PAN-90806 Ophthalmic Solution, Lucentis - Age-Related Macular Degeneration (AMD) | Phase 1 | Completed | PanOptica, Inc. | 50 | 2014-02-01 | 2016-09-28 |
| A Safety and Efficacy Trial of a Treat and Extend Protocol Using Ranibizumab With and Without Laser Photocoagulation for Diabetic Macular Edema Ranibizumab 0.3 mg intravitreal injection, Guided Laser Photocoagulation - Diabetic Macular Edema | Phase 1 / Phase 2 | Completed | Palmetto Retina Center, LLC | 150 | 2013-11-01 | 2020-11-17 |
| Safety Study of PF582 Versus Lucentis in Patients With Age Related Macular Degeneration Lucentis, PF582 - Age Related Macular Degeneration (AMD) | Phase 1 / Phase 2 | Completed | Pfenex, Inc | 25 | 2013-11-01 | 2016-05-11 |
| Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration Ranibizumab 0.5mg, Aflibercept 2.0mg - Neovascular Age-Related Macular Degeneration | Phase 1 / Phase 2 | Completed | Arshad Khanani | 100 | 2013-09-01 | 2016-03-03 |
| Study of Squalamine Lactate for the Treatment of Macular Edema Related to Retinal Vein Occlusion ranibizumab, Squalamine Lactate Ophthalmic Solution, 0.2% - Retinal Vein Occlusion, Macular Edema | Phase 1 / Phase 2 | Completed | Ohr Pharmaceutical Inc. | 20 | 2013-04-01 | 2015-11-25 |
| Ranibizumab For Persistent Diabetic Macular Edema After Bevacizumab Ranibizumab 0.3mg/0.05cc - Diabetic Macular Edema | Phase 1 / Phase 2 | Unknown | Southeast Retina Center, Georgia | 30 | 2013-04-01 | 2014-09-17 |
| Reduced-fluence Verteporfin Photodynamic Therapy Plus Ranibizumab for Choroidal Neovascularization in Pathologic Myopia PDT standard fluence, ranibizumab, PDT reduced fluence, ranibizumab, ranibizumab - Myopia, Degenerative | Phase 1 | Completed | University of Campania Luigi Vanvitelli | 60 | 2012-06-01 | 2013-10-28 |
| Efficacy & Safety Trial of Intravitreal Injections Combined With PRP for CSME Secondary to Diabetes Mellitus (DAVE) 0.3 mg ranibizumab, Targeted Pan Retinal Photocoagulation - Diabetic Macular Edema | Phase 1 / Phase 2 | Completed | David M. Brown, M.D. | 29 | 2012-03-01 | 2018-10-05 |
| Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGF Blood Sample Collection, Aflibercept, Bevacizumab - Age-related Macular Degeneration, Diabetic Macular Edema | Phase 1 / Phase 2 | Completed | California Retina Consultants | 56 | 2012-03-01 | 2016-05-19 |
| Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab ranibizumab 0.5mg, ranibizumab 1.0mg - Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion | Phase 1 / Phase 2 | Completed | Hanscom, Thomas, M.D. | 14 | 2011-11-01 | 2015-04-29 |
| Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy ranibizumab 0.5 or 2.0 mg/0.05 cc - Polypoidal Choroidal Vasculopathy | Phase 1 / Phase 2 | Completed | Southeast Retina Center, Georgia | 20 | 2011-09-01 | 2022-12-12 |
| Ranibizumab for the Management of Recurrent Nosebleeds in Patients With Hereditary Hemorrhagic Telangiectasia (HHT) Ranibizumab - Hereditary Hemorrhagic Telangiectasia (HHT), Nosebleeds | Phase 1 | Withdrawn | University of California, San Diego | 2011-07-01 | 2013-04-29 | |
| High Dose Intravitreal Ranibizumab for Recalcitrant Radiation Retinopathy ranibizumab 2.0 mg - Radiation Retinopathy | Phase 1 | Completed | The New York Eye Cancer Center | 10 | 2011-05-01 | 2014-10-02 |
Showing 20 of 49. Sign in to see all of them.
Macular Degeneration (7) · Macular Edema (7) · Retinal Vein Occlusion (7) · Choroidal Neovascularization (4) · Polypoidal Choroidal Vasculopathy (4) · Retinal Diseases (4) · Corneal Neovascularization (2) · Diabetes Mellitus (2) · Diabetic Retinopathy (2) · Edema (2) · Eye Diseases (2) · Glaucoma, Neovascular (2) · Myopia, Degenerative (2) · Uveal Melanoma (2) · Uveitis (2)
California Retina Consultants (3) · David M. Brown, M.D. (3) · Johns Hopkins University (3) · Southeast Retina Center, Georgia (3) · The New York Eye Cancer Center (3) · University of Miami (3) · University of Illinois at Chicago (2) · Arshad Khanani (1) · Bhagat, Neelakshi, M.D., M.P.H. (1) · Clement K. Chan (1) · Daiichi Sankyo (1) · Hanscom, Thomas, M.D. (1) · Hawaii Pacific Health (1) · Jang Won Heo (1) · Justis Ehlers (1)
United States (38) · China (1) · Japan (1) · New Zealand (1) · South Korea (1)
David M Brown, MD (2) · Dennis M. Marcus, M.D. (2) · Neil M. Bressler, MD (2) · Paul T Finger, MD (2) · Sonia Yoo, MD (2) · Arshad M Khanani, MD (1) · Charles C Wykoff, MD, PhD (1) · Clement K Chan, M.D. (1) · Dante J Pieramici, M.D. (1) · Dante Pieramici, MD (1) · Dennis M Marcus, M.D. (1) · Diana V Do, MD (1) · Flavia Chiosi, MD (1)
PMID 20142553, PMID 20163368, PMID 20417925, PMID 20827138, PMID 21232078, PMID 21742303, PMID 22186988, PMID 22457045, PMID 22990319, PMID 25001321, PMID 25102193, PMID 25277305, PMID 25633882, PMID 27836430, PMID 29729809, PMID 32303499, PMID 40522203, PMID 42064470